Van Thuy Mai Nguyen

Van Thuy Mai Nguyen

Auto-generated profile, based on publicly available information

Van Thuy Mai Nguyen

Department of Surgery and Cancer, Imperial College London, London, UK

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 October 2016 in Oncogene
Verified
Journal Article
Open access
AHA Harrod
A Harrod
JFJ Fulton
J Fulton
VNV T M Nguyen
V T M Nguyen
MPM Periyasamy
M Periyasamy
LRL Ramos-Garcia
L Ramos-Garcia
SASimak Ali
Simak Ali
Drugs that inhibit estrogen receptor-α (ER) activity have been highly successful in treating and reducing breast cancer progression in ER-positive disease. However, resistance to these therapies presents a major clinical problem. Recent genetic studies have shown that mutations in the ER gene are found in >20% of tumours that progress on endocrine therapies. Remarkably, the great majority of these mutations localize to just a few amino acids within or near the critical helix 12 region of the ER hormone binding domain, where they are likely to be single allele mutations. Understanding how these mutations impact on ER function is a prerequisite for identifying methods to treat breast cancer patients featuring such mutations. Towards this end, we used CRISPR-Cas9 genome editing to make a single allele knock-in of the most commonly mutated amino acid residue, tyrosine 537, in the estrogen-responsive MCF7 breast cancer cell line. Genomic analyses using RNA-seq and ER ChIP-seq demonstrated that the Y537S mutation promotes constitutive ER activity globally, resulting in estrogen-independent growth. MCF7-Y537S cells were resistant to the anti-estrogen tamoxifen and fulvestrant. Further, we show that the basal transcription factor TFIIH is constitutively recruited by ER-Y537S, resulting in ligand-independent phosphorylation of Serine 118 (Ser118) by the TFIIH kinase, cyclin-dependent kinase (CDK)7. The CDK7 inhibitor, THZ1 prevented Ser118 phosphorylation and inhibited growth of MCF7-Y537S cells. These studies confirm the functional importance of ER mutations in endocrine resistance, demonstrate the utility of knock-in mutational models for investigating alternative therapeutic approaches and highlight CDK7 inhibition as a potential therapy for endocrine-resistant breast cancer mediated by ER mutations.

10 May 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
Silvia OttavianiSilvia Ottaviani
Silvia Ottaviani
JSJustin Stebbing
Justin Stebbing
Adam E. FramptonAdam E. Frampton
Adam E. Frampton
SZSladana Zagorac
Sladana Zagorac
JKJonathan Krell
Jonathan Krell
Leandro CastellanoLeandro Castellano
Leandro Castellano
TGF-β/Activin induces epithelial-to-mesenchymal transition and stemness in pancreatic ductal adenocarcinoma (PDAC). However, the microRNAs (miRNAs) regulated during this response have remained yet undetermined. Here, we show that TGF-β transcriptionally induces MIR100HG lncRNA, containing miR-100, miR-125b and let-7a in its intron, via SMAD2/3. Interestingly, we find that although the pro-tumourigenic miR-100 and miR-125b accordingly increase, the amount of anti-tumourigenic let-7a is unchanged, as TGF-β also induces LIN28B inhibiting its maturation. Notably, we demonstrate that inactivation of miR-125b or miR-100 affects the TGF-β-mediated response indicating that these miRNAs are important TGF-β effectors. We integrate AGO2-RIP-seq with RNA-seq to identify the global regulation exerted by these miRNAs in PDAC cells. Transcripts targeted by miR-125b and miR-100 significantly overlap and mainly inhibit p53 and cell–cell junctions’ pathways. Together, we uncover that TGF-β induces an lncRNA, whose encoded miRNAs, miR-100, let-7a and miR-125b play opposing roles in controlling PDAC tumourigenesis.

1 October 2015 in Cell Reports
Verified
Journal Article
Open access
MPManikandan Periyasamy
Manikandan Periyasamy
HPHetal Patel
Hetal Patel
CLChun-Fui Lai
Chun-Fui Lai
VNVan T.M. Nguyen
Van T.M. Nguyen
ENEkaterina Nevedomskaya
Ekaterina Nevedomskaya
SASimak Ali
Simak Ali
Estrogen receptor α (ERα) is the key transcriptional driver in a large proportion of breast cancers. We report that APOBEC3B (A3B) is required for regulation of gene expression by ER and acts by causing C-to-U deamination at ER binding regions. We show that these C-to-U changes lead to the generation of DNA strand breaks through activation of base excision repair (BER) and to repair by non-homologous end-joining (NHEJ) pathways. We provide evidence that transient cytidine deamination by A3B aids chromatin modification and remodelling at the regulatory regions of ER target genes that promotes their expression. A3B expression is associated with poor patient survival in ER+ breast cancer, reinforcing the physiological significance of A3B for ER action.

15 June 2015 in Oncotarget
Verified
Journal Article
Open access
LMLuca Magnani
Luca Magnani
DPDarren K. Patten
Darren K. Patten
VNVan T. M. Nguyen
Van T. M. Nguyen
SHSung-Pil Hong
Sung-Pil Hong
JSJennifer H. Steel
Jennifer H. Steel
RCR. Charles Coombes
R. Charles Coombes
The pioneer factor PBX1 is a novel driver of metastatic progression in ERα-positive breast cancer The pioneer factor PBX1 is a novel driver of metastatic progression in ERα-positive breast cancer

4 June 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
MFMonica Faronato
Monica Faronato
VNVan T.M. Nguyen
Van T.M. Nguyen
DPDarren K. Patten
Darren K. Patten
YLYlenia Lombardo
Ylenia Lombardo
JSJennifer H. Steel
Jennifer H. Steel
LMLuca Magnani
Luca Magnani
DMXL2 drives epithelial to mesenchymal transition in hormonal therapy resistant breast cancer through Notch hyper-activation DMXL2 drives epithelial to mesenchymal transition in hormonal therapy resistant breast cancer through Notch hyper-activation

1 August 2015 in Cell Reports
Verified
Journal Article
Open access
YXYichen Xu
Yichen Xu
HZHua Zhang
Hua Zhang
VNVan Thuy Mai Nguyen
Van Thuy Mai Nguyen
NANicos Angelopoulos
Nicos Angelopoulos
JNJoao Nunes
Joao Nunes
Georgios GiamasGeorgios Giamas
Georgios Giamas
LMTK3 is an oncogenic receptor tyrosine kinase (RTK) implicated in various types of cancer, including breast, lung, gastric, and colorectal cancer. It is localized in different cellular compartments, but its nuclear function has not been investigated so far. We mapped LMTK3 binding across the genome using ChIP-seq and found that LMTK3 binding events are correlated with repressive chromatin markers. We further identified KRAB-associated protein 1 (KAP1) as a binding partner of LMTK3. The LMTK3/KAP1 interaction is stabilized by PP1α, which suppresses KAP1 phosphorylation specifically at LMTK3-associated chromatin regions, inducing chromatin condensation and resulting in transcriptional repression of LMTK3-bound tumor suppressor-like genes. Furthermore, LMTK3 functions at distal regions in tethering the chromatin to the nuclear periphery, resulting in H3K9me3 modification and gene silencing. In summary, we propose a model where a scaffolding function of nuclear LMTK3 promotes cancer progression through chromatin remodeling.